- Home
- YALA vs CRVS Comparison
YALA vs CRVS Comparison
Compare YALA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | CRVS |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | YALA | CRVS |
|---|---|---|
| Price | $6.56 | $14.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $28.20 |
| AVG Volume (30 Days) | 323.6K | ★ 1.1M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $7.13 | N/A |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.13 | $2.80 |
| 52 Week High | $9.29 | $26.95 |
Technical Indicators
Market Signals| Indicator | YALA | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 48.28 |
| Support Level | $6.04 | $12.95 |
| Resistance Level | $7.32 | $18.73 |
| Average True Range (ATR) | 0.23 | 0.89 |
| MACD | 0.06 | 0.16 |
| Stochastic Oscillator | 77.56 | 72.69 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.